ADELINE ABAM: Open Payments
NPI 1902277056 · FORT WORTH, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,217 in 66 payments from 8 companies in 2025. Trend: 2023 $173 · 2024 $644 · 2025 $1,217
Food & beverage: $1,217
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 15 | $216 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 17 | $212 |
| Janssen Pharmaceuticals, Inc | 5 | $179 |
| Neurocrine BioSciences, Inc. | 5 | $162 |
| Otsuka America Pharmaceutical, Inc. | 10 | $155 |
| Alkermes, Inc. | 7 | $138 |
| Luye Pharma (USA) Ltd. | 4 | $92 |
| Teva Pharmaceuticals USA, Inc. | 3 | $64 |
Products named: COBENFY, CAPLYTA, INVEGA SUSTENNA, INGREZZA, REXULTI, ERZOFRI EXTENDED-RELEASE, ARISTADA, LYBALVI.
Industry payments across TX — which companies pay providers there.
